ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: US04272N1028
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CDT Equity Inc. Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.	United States of America	CDT
CELADON PHARMACEUTICALS PLC Vertically integrated pharma developing cannabis medicines for chronic pain.	United Kingdom	CEL
Celcuity Inc. Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.	United States of America	CELC
Celemics, Inc. Develops custom NGS panels and bioinformatics for research and clinical diagnostics.	South Korea	331920
Cellbion Co., Ltd Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.	South Korea	308430
CELL BIOTECH CO ., LTD A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.	South Korea	049960
Celldex Therapeutics, Inc. Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.	United States of America	CLDX
Cellectar Biosciences, Inc. Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.	United States of America	CLRB
Cellectis Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.	France	ALCLS
Cellectis S.A. Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.	United States of America	CLLS